eISSN 1738-8872
pISSN 1017-7825
pISSN 1017-7825
Table. 3.
Table. 3.
Detailed information on the top 10 sensitive drugs.
| Drug name | Drug target | Target pathway | Introduction |
|---|---|---|---|
| AZD1332 | NTRK1, NTRK2, NTRK3 | RTK signaling | AZD1332 is a potent, selective, ATP-competitive neurotrophic tyrosine kinase receptor. |
| AZD7762 | CHEK1, CHEK2 | Cell cycle | AZD-7762 (AZD7762) is a potent and selective inhibitor of Chk1/2，enhances the radiosensitivity of mutated p53 tumor cell lines and HT29 xenografts. |
| Dasatinib | ABL,SRC,Ephrins, PDGFR, KIT | Other | Dasatinib inhibits tumor growth and spread by inhibiting the activity of BCR-ABL and other kinases, as well as interfering with aberrant signaling pathways, and is an important drug used in the treatment of leukemia and other malignancies. |
| AZD8055 | MTORC1, MTORC2 | PI3K/MTOR signaling | AZD8055, as a bi-directional mTOR inhibitor, has the potential to be used as a therapeutic agent for the treatment of tumors by inhibiting the growth, live and metastatic ability of tumor cells through the inhibition of both components of the mTOR signaling pathway. |
| Entinostat | HDAC1, HDAC3 | Chromatin histone acetylation | Entinostat, as an HDAC inhibitor, mainly works by regulating chromatin structure and gene transcription, affecting the cell cycle, DNA repair, etc. thereby inhibiting tumor cell proliferation and growth. |
| GSK269962A | ROCK1, ROCK2 | Cytoskeleton | GSK269962A represents a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases. |
| Nilotinib | ABL | ABL signaling | Nilotinib is a drug used to treat chronic myeloid leukemia and certain acute lymphoblastic leukemias by inhibiting the activity of BCR-ABL and other related tyrosine kinases, interfering with aberrant signaling pathways, and inhibiting the proliferation and inducing the apoptosis of leukemia cells. |
| Ruxolutinib | JAK 1?TYK 2 | JAK signaling | Ruxolitinib, as a JAK inhibitor, interferes with cytokine signaling pathways and inhibits the activation of aberrant signaling pathways by inhibiting the activity of kinases such as JAK1 and JAK2, and has immunomodulatory effects. |
| SB505124 | TGFBR1, ACVR1B, ACVR1C | RTK signaling | SB505124 acts as an inhibitor of the TGF-β signaling pathway, and its main role is to block TGF-β signaling by inhibiting TGF-β receptor activity, inhibiting the proliferation, migratory and invasive ability of tumor cells. |
| Wnt.c59 | PORCN | Wnt signaling | By inhibiting the Wnt signaling pathway, Wnt.c59 can play a regulatory role in a variety of cells and tissues. |
J. Microbiol. Biotechnol. 2024;34:1164~1177 https://doi.org/10.4014/jmb.2310.10052
© J. Microbiol. Biotechnol.